Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28674266 | 0.90 | GPR119 (0.45) | GPR119POLBSTSTGFBR1 | |
| SCHEMBL23923085 | 0.85 | GPR119 (0.47) | GPR119STSTRPV1 | |
| SCHEMBL23293120 | 0.84 | GPR119 (0.47) | GPR119POLBSTSTGFBR1 | |
| SCHEMBL23293089 | 0.82 | GPR119 (0.52) | GPR119POLB | |
| SCHEMBL29487581 | 0.82 | GPR119 (0.52) | GPR119POLB | |
| SCHEMBL23923086 | 0.79 | GPR119 (0.43) | GPR119STSTRPV1 | |
| SCHEMBL23922943 | 0.79 | TRPV1 (0.45) | GPR119STSTRPV1 | |
| SCHEMBL20818548 | 0.76 | ALDH1A1 (0.52) | GPR119POLB | |
| SCHEMBL30476362 | 0.76 | ALDH1A1 (0.52) | GPR119POLB | |
| SCHEMBL28666876 | 0.75 | HCRTR2 (0.42) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | GPR119 56/4885POLB 4654/4885STS 1498/4885 |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | GPR119 56/4885POLB 4654/4885STS 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.